Lupin obtains FDA OK for generic Doryx
Generic Doryx is a tetracycline-class antimicrobial indicated as adjunctive therapy for severe acne.
Lupin has received the Food and Drug Administration’s green light for Doxycycline Hyclate Delayed-Release tablets, 50 mg, 60 mg, 75 mg, 80 mg, 100 mg, 120 mg, 150 mg and 200 mg, which is the generic of Mayne’s Doryx Delayed-Release tablets and Doryx MPC Delayed-Release tablets.
The medication is a tetracycline-class antimicrobial indicated as adjunctive therapy for severe acne.
This product will be manufactured at Lupin’s Pithampur facility in India.
[Read more: Lupin receives FDA OK for generic Banzel]
Doxycycline Hyclate Delayed-Release tablets (Doryx ) had a market value of approximately $9 million, per June 2023 IQVIA data.
[Read more: Lupin receives FDA OK for generic Derma Smoothe/FS]